120 related articles for article (PubMed ID: 27878232)
1. Involvement of bleomycin hydrolase and poly(ADP-ribose) polymerase-1 in Ubc9-mediated resistance to chemotherapy agents.
Chen Y; Zhang H; He Q
Int J Oncol; 2017 Jan; 50(1):223-231. PubMed ID: 27878232
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of UBC9 increases the sensitivity of hepatocellular carcinoma to doxorubicin.
Fang S; Qiu J; Wu Z; Bai T; Guo W
Oncotarget; 2017 Jul; 8(30):49783-49795. PubMed ID: 28572537
[TBL] [Abstract][Full Text] [Related]
3. An evolutionarily conserved cysteine protease, human bleomycin hydrolase, binds to the human homologue of ubiquitin-conjugating enzyme 9.
Koldamova RP; Lefterov IM; DiSabella MT; Lazo JS
Mol Pharmacol; 1998 Dec; 54(6):954-61. PubMed ID: 9855622
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor alpha and nuclear factor Y coordinately regulate the transcription of the SUMO-conjugating UBC9 gene in MCF-7 breast cancer cells.
Ying S; Dünnebier T; Si J; Hamann U
PLoS One; 2013; 8(9):e75695. PubMed ID: 24086615
[TBL] [Abstract][Full Text] [Related]
5. Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study.
Quinonero F; Cepero A; Urbano D; Munoz-Gamez JA; Martin-Guerrero SM; Martin-Oliva D; Prados J; Melguizo C; Ortiz R
J Biosci; 2021; 46():. PubMed ID: 33576344
[TBL] [Abstract][Full Text] [Related]
6. Ubc9 expression predicts chemoresistance in breast cancer.
Chen SF; Gong C; Luo M; Yao HR; Zeng YJ; Su FX
Chin J Cancer; 2011 Sep; 30(9):638-44. PubMed ID: 21880185
[TBL] [Abstract][Full Text] [Related]
7. Nuclear accumulation of UBC9 contributes to SUMOylation of lamin A/C and nucleophagy in response to DNA damage.
Li Y; Jiang X; Zhang Y; Gao Z; Liu Y; Hu J; Hu X; Li L; Shi J; Gao N
J Exp Clin Cancer Res; 2019 Feb; 38(1):67. PubMed ID: 30744690
[TBL] [Abstract][Full Text] [Related]
8. FOXP3 Activates SUMO-Conjugating
Wang CM; Yang WH; Liu R; Wang L; Yang WH
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011797
[TBL] [Abstract][Full Text] [Related]
9. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin.
Hastak K; Alli E; Ford JM
Cancer Res; 2010 Oct; 70(20):7970-80. PubMed ID: 20798217
[TBL] [Abstract][Full Text] [Related]
10. Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group.
Bredenfeld H; Franklin J; Nogova L; Josting A; Fries S; Mailänder V; Oertel J; Diehl V; Engert A;
J Clin Oncol; 2004 Jun; 22(12):2424-9. PubMed ID: 15136597
[TBL] [Abstract][Full Text] [Related]
11. Ubiquitin-conjugating enzyme 9 promotes epithelial ovarian cancer cell proliferation in vitro.
Dong M; Pang X; Xu Y; Wen F; Zhang Y
Int J Mol Sci; 2013 May; 14(6):11061-71. PubMed ID: 23708104
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA H19 regulates proliferation and doxorubicin resistance in MCF-7 cells by targeting PARP1.
Wang Y; Zhou P; Li P; Yang F; Gao XQ
Bioengineered; 2020 Dec; 11(1):536-546. PubMed ID: 32345117
[TBL] [Abstract][Full Text] [Related]
13. An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.
Awada A; Campone M; Varga A; Aftimos P; Frenel JS; Bahleda R; Gombos A; Bourbouloux E; Soria JC
Anticancer Drugs; 2016 Apr; 27(4):342-8. PubMed ID: 26796987
[TBL] [Abstract][Full Text] [Related]
14. The nuclear expression of poly (ADP-ribose) polymerase-1 (PARP1) in invasive primary breast tumors is associated with chemotherapy sensitivity.
Zhai L; Li S; Li X; Li H; Gu F; Guo X; Liu F; Zhang X; Fu L
Pathol Res Pract; 2015 Feb; 211(2):130-7. PubMed ID: 25480692
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
Ma X; Dang C; Min W; Diao Y; Hui W; Wang X; Dai Z; Wang X; Kang H
Breast Cancer Res Treat; 2019 Jul; 176(1):109-117. PubMed ID: 30989461
[TBL] [Abstract][Full Text] [Related]
16. Ubc9 promotes breast cell invasion and metastasis in a sumoylation-independent manner.
Zhu S; Sachdeva M; Wu F; Lu Z; Mo YY
Oncogene; 2010 Mar; 29(12):1763-72. PubMed ID: 20023705
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line.
Biliran H; Wang Y; Banerjee S; Xu H; Heng H; Thakur A; Bollig A; Sarkar FH; Liao JD
Clin Cancer Res; 2005 Aug; 11(16):6075-86. PubMed ID: 16115953
[TBL] [Abstract][Full Text] [Related]
18. Therapy of Smac mimetic SM-164 in combination with gemcitabine for pancreatic cancer.
Zhou B; Zhang J; Chen G; You L; Zhang TP; Zhao YP
Cancer Lett; 2013 Feb; 329(1):118-24. PubMed ID: 23142291
[TBL] [Abstract][Full Text] [Related]
19. SUMOylation stabilizes hSSB1 and enhances the recruitment of NBS1 to DNA damage sites.
Zhou L; Zheng L; Hu K; Wang X; Zhang R; Zou Y; Zhong L; Wang S; Wu Y; Kang T
Signal Transduct Target Ther; 2020 Jun; 5(1):80. PubMed ID: 32576812
[TBL] [Abstract][Full Text] [Related]
20. Site-specific inhibition of the small ubiquitin-like modifier (SUMO)-conjugating enzyme Ubc9 selectively impairs SUMO chain formation.
Wiechmann S; Gärtner A; Kniss A; Stengl A; Behrends C; Rogov VV; Rodriguez MS; Dötsch V; Müller S; Ernst A
J Biol Chem; 2017 Sep; 292(37):15340-15351. PubMed ID: 28784659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
